Condition: Glioblastoma Multiforme (GBM) · Pancreatic Ductal Adenocarcinoma (PDAC) · Sponsor: Radiomedix, Inc.
The goal of this Phase I clinical trial is to evaluate how the imaging drug 203Pb- RMX-VH-PIB distributes in the body and how much radiation different organs receive in patients with glioblastoma multiforme (GBM) or pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: How does 203Pb-RMX-VH-PIB spread in the body (biodistribution)? What is the radiation dose delivered to organs (dosimetry)? Participants will: Receive a single IV injection of 203Pb-RMX-VH-PIB. Undergo multiple SPECT/CT imaging scans. Have blood, urine, vital signs, and ECG monitored for safety. Be followed for any side effects for up to 30 days.
This description comes directly from the study's public registry record.
Ebrahim Delpassand, MD, FACNM · 713-499-9733 · edelpassand@radiomedix.com
Izabela Tworowska, MS Pharm Clinical, Ph.D · 832-868-2812 · itworowska@radiomedix.com
Always discuss trial participation with your own doctor first.
| Excel Diagnostics & Nuclear Oncology Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07733674